Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-08

Clinical Trial Update: An Open Label Extension Study of the Efficacy of MORAb-003 [Phase 2]

View source ↗

Summary

Open-label extension study of MORAb-003 (epithelial ovarian cancer) in Phase 2 has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MORAb-003 (farletuzumab)

Snippet

Sponsor: Morphotek | Conditions: Epithelial Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-12-08